North America Urinary Tract Infections Market

North America Urinary Tract Infections Market Size (2024 to 2029)

The Urinary Tract Infections Market size in North America is estimated to be worth USD 2.2 billion by 2029 and USD 1.99 billion in 2024, growing at a CAGR of 2.04% during the forecast period.

The rising prevalence of Urinary tract infections across the region is majorly contributing to the Urinary tract infections market in North America. Also, the growing hospital-borne infections and growing geriatric population are likely to fuel the market growth. While women's urethras are smaller and closer to the anus than men's, they are at a higher risk of having UTIs than males. In women, the physical configuration of the urinary system enhances the odds of germs being transferred to the bladder. The illness, however, can afflict persons of any gender or age.

To be competitive in the urinary tract infection treatment market, leading companies focus on developing manufacturing facilities and securing long-term distribution partnerships with key local distribution organizations. In terms of drug class, Quinolones are projected to lead the urinary tract infection treatment market over the forecast period. Since antibiotics are the sole therapy for urinary tract infections (UTIs), the market for UTI treatment is expected to rise. Furthermore, the loss of patent rights for branded medications and the development of branded generics and generic drugs are expected to enhance the market for urinary tract infection therapy.

Similarly, in instances of less severe infections, fluoroquinolones such as ciprofloxacin or ofloxacin are given for difficult urinary tract infection therapy. Aside from these, the loss of patent rights for branded medications and the availability of low-cost antibiotics from generic firms are two other factors anticipated to drive the expansion of the urinary tract infection treatment market. Furthermore, due to the growing prevalence of urinary tract infections and the rise in hospital visits for urinary tract infection treatment and therapy, the urinary tract infection treatment market is projected to develop significantly.

Furthermore, the increasing demand for antibiotics in treating urinary tract infections and increased generic players are expected to drive the urinary tract infection treatment market further.

However, increasing market fragmentation and unmet clinical requirements are some factors that might hinder the North American Urinary tract infections market growth.

This research report on the North American Urinary Tract Infections Market has been segmented and sub-segmented into the following categories:

North American Urinary Tract Infections Market - By Type of Medication:

• Penicillin & Combinations 
  • Amoxicillin
  • Amoxicillin-Clavulanate Potassium combination
• Quinolones             
  • Ciprofloxacin
  • Levofloxacin
  • Norfloxacin
  • Nalidixic Acid
• Aminoglycoside-Antibodies             
  • Gentamicin
  • Amikacin
• Cephalosporin       
  • Ceftriaxone
  • Cefixime
  • Cefuroxime
  • Cephalexin
• Sulphonamides     
  • Sulfamethoxazole
  • Trimethoprim combination
• Azoles & Amphotericin B  
• Tetracycline            
  • Doxycycline
  • Nitrofurans
• Nitrofurans 

North American Urinary Tract Infections Market - By Type of Indication:

• Uncomplicated UTI
• Complicated UTI   
• Recurring Complicated UTI               
• Neurogenic Bladder Infection 

North American Urinary Tract Infections Market - By Country:

• The United States
• Canada
• Rest of North America

Regionally, North America has the third-largest market in the world for urinary tract infections by share. In the North American region, the United States has the largest market share, while Canada is expected to grow faster. Factors such as the increasing geriatric population and growing disposable incomes are expected to propel market growth in the region. Additionally, factors such as the growing demand for antibiotics, low cost of drugs, and rising hospital-borne infections propel market growth. In addition, rising awareness of women's healthcare and increasing investment and funding by the government and private organizations are encouraging market growth. However, advanced economies like the United States and Canada have seen development in the urinary tract infection treatment market due to rising government healthcare expenditure efforts and increased awareness of urinary tract infection therapy. Therefore, the United States and Canada are largely contributing to the North American regional market growth. Over the forecast period, the United States accounted for the largest share of the market. Also, Various manufacturers in North America are exploring strategic partnerships and acquisitions with various firms and distribution channels to boost product sales and improve company operations. Therefore, the Urinary Tract Infections Market is more likely to have a promising share in Canada owing to the growing focus on women's healthcare and increasing healthcare expenditure.

KEY MARKET PLAYERS:

A few of the notable companies leading the North America Urinary Tract Infections market profiled in this report are Pfizer, Inc., AstraZeneca plc, Johnson & Johnson, Novartis International AG., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd., among others.